| Value | ₹1,250 Cr |
|---|
BSE filing, NSE: NOVARTIND. Summary written from the filing by ALFA Finder's alert engine.
Novartis India Ltd: key numbers
- Share price
- ₹1,805.95
- Market cap
- ₹4,459 Cr
- Revenue (annual)
- ₹354.3 Cr
- Net profit (annual)
- ₹93.18 Cr
- P/E (TTM)
- 45.6×Sector 46.1×
- Promoter holding
- 70.68%+0.00% QoQ
- FII holding
- 1.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Novartis India Ltd
All →Novartis India Management Change
Evonile Pharma (formerly Novartis India) appointed Mr. Gagan Sharma as President – Specialty Business and Senior Management Personnel effective October 26, 2026. The filing is a Regulation 30 senior management appointment intimation.
Novartis India Other Announcement
Novartis India Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations. This is a routine periodic disclosure.
Novartis India Annual General Meeting
Evonile Pharma (fka Novartis India) issued a postal ballot notice for shareholder votes on ESOP 2026 grant to the MD & CEO and creation of charge on assets. E-voting runs 14 Oct–12 Nov 2026.
Novartis India Fund Raise of ₹900 Cr
Evonile Pharma Limited approved a rights issue to raise up to ₹900 Crore. The company also formed a committee to manage the issuance terms.
- Value
- ₹900.0 Cr
Novartis India Credit Rating
Evonile Pharma Limited has received credit ratings from CARE Ratings Limited for its bank facilities. The company disclosed the ratings as part of its regulatory filings.
Novartis India Other Announcement
Novartis India Limited has changed its corporate name to Evonile Pharma Limited, effective October 01, 2026, following approval from the Ministry of Corporate Affairs.
Other acquisition announcements
All →Embassy Developments Acquisition Worth ₹32.65 Cr
Embassy Developments signed an SPA to acquire 50% of Embassy Columbia Pacific ASL for ₹32.65 Crore. The JV will become wholly owned upon closing by December 2026.
- Value
- ₹32.65 Cr
- Execution
- Within the current quarter ending on December 31, 2026
MosChip Technologies Acquisition Worth ₹266.7 Cr
MosChip will acquire Vayavya Labs for Rs.266.71 Crore in cash and shares. Completion awaits RBI and exchange approvals and shareholder approval of a preferential issue.
- Value
- ₹266.7 Cr
- Execution
- Within 15 days of the later of receipt of all requisite approvals or shareholder approval of the preferential issue to VLPL sellers
Hexaware Technologies Acquisition
Hexaware Technologies announced amalgamation of two wholly owned step-down subsidiaries into its Canadian subsidiary. No cash consideration is involved, and the merger is internal group restructuring.
Zensar Technologies Acquisition
Zensar's board approved merging its wholly owned subsidiary M3bi India into the parent. No consideration or share issuance is involved, and NCLT sanction is pending.
ICICI Lombard General Insurance Company Acquisition Worth ₹172 Cr
ICICI Lombard disclosed that it acquired Rs.172 Crore of State Bank of India shares on October 28, 2026, in its ordinary-course investment function. Its cumulative holding in SBI is now 0.02%.
- Value
- ₹172.0 Cr
- Execution
- Investment made in multiple tranches over a period of time
Emkay Global Financial Services Acquisition Worth ₹30 Cr
Emkay Global will buy Emkay Capital Private Limited for Rs 30 Crore in cash. The related-party deal is expected to complete within 90 days.
- Value
- ₹30.00 Cr